
    
      Observational study cost-effectivity to compare the treatment in neutropenic patients after
      allogenic blood stem cell transplantation, with meropenem or meropenem plus glycopeptide.

      The study will be done in two consecutive cohorts of patients. First cohort: meropenem 1g/8h
      ev Second cohort: meropenem 1g/8h and glycopeptide (vancomycin 1g/12 h or teicoplanin 400
      mg/24h)
    
  